Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Changing perspective on immunization against influenza.

Bert E Johansson1, Ian C Brett

  • 1Innovation Sciences, Armonk, NY 10504, USA. bertjoh@pol.net

Vaccine
|February 6, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers.

eLife·2023
Same author

Emergency Medical Service Personnel Recognize Pediatric Concussions.

Global pediatric health·2017
Same author

Case 3: Acute Onset of Headache, Fever, and Right Arm Weakness in 12-year-old Boy.

Pediatrics in review·2015
Same author

Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation.

Proceedings of the National Academy of Sciences of the United States of America·2013
Same author

Synthesis, purification, and characterization of single helix membrane peptides and proteins for NMR spectroscopy.

Methods in molecular biology (Clifton, N.J.)·2011
Same author

Influenza viral neuraminidase: the forgotten antigen.

Expert review of vaccines·2011
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
Same journal

Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.

Vaccine·2026
Same journal

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.

Vaccine·2026
See all related articles

Current influenza vaccines, reliant on hemagglutinin (HA), offer limited protection due to viral mutations. Including neuraminidase (NA) in vaccines could broaden immunity and improve protection against evolving influenza strains.

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Current influenza vaccines utilize outdated, labor-intensive methods based on embryonated chicken eggs.
  • Immunity from existing vaccines is primarily directed against the hemagglutinin (HA) surface glycoprotein.
  • This HA-centric immunity is vulnerable to influenza virus antigenic drift and shift, leading to reduced vaccine efficacy and short-lived protection.

Purpose of the Study:

  • To advocate for a revised influenza vaccine strategy incorporating both hemagglutinin (HA) and neuraminidase (NA) glycoproteins.
  • To explore alternative, more efficient vaccine production technologies to shorten manufacturing timelines.

Main Methods:

  • The study proposes a shift in vaccine composition to include both HA and NA.
  • It suggests investigating alternative production platforms like recombinant baculovirus and yeast systems.

Related Experiment Videos

Main Results:

  • Including neuraminidase (NA) in influenza vaccines is predicted to broaden the immune response.
  • A broader immune response, encompassing both HA and NA, would enhance protection against evolving influenza viruses.
  • Alternative production methods could significantly decrease vaccine manufacturing times.

Conclusions:

  • A strategic shift to include both HA and NA in influenza vaccines is necessary to overcome current limitations.
  • Incorporating the more conserved NA component will improve vaccine resilience against viral antigenic changes.
  • Exploring novel production technologies is crucial for timely and efficient influenza vaccine development.